US4497781090 - Common Stock
IO BIOTECH INC
NASDAQ:IOBT (9/16/2024, 3:03:56 PM)
0.7654
+0.02 (+2.05%)
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
IO BIOTECH INC
Ole Maaloes Veh 3
COPENHAGEN
P: 4570702980
Employees: 68
Website: https://www.iobiotech.com/
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head...
Let's take a look at the stocks that are in motion in today's session.
Which stocks are experiencing notable movement on Tuesday?
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Here you can normally see the latest stock twits on IOBT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: